E-2101
E-2101 is a novel antispastic agent. E-2101 is a competitive CYP2C19 and CYP2D6 inhibitor with Ki values of 15 and 48 μM, respectively. E-2101 is metabolized by Cytochromes P450 to form monohydroxylated (M1 and M2), dihydroxylated (M3), and N-dealkylated metabolites (M4) . E-2101 can be used in the research of skeletal muscle spasm[1].
Product Specifications
CAS Number
265667-22-9
UNSPSC
12352005
Target
Cytochrome P450
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Others
Smiles
O=C(NC)CC1=CC2=C(C=C1)C=CN2C3CCN(CCC4=CC=CC=C4F)CC3
Molecular Formula
C24H28FN3O
Molecular Weight
393.50
References & Citations
[1]Zhang ZY, et al. In vitro interactions between a potential muscle relaxant E2101 and human cytochromes P450. Drug Metab Dispos. 2002 Jul;30 (7) :805-13. |[2]Kushida, et al. Solid state characterization of E2101, a novel antispastic drug. J Pharm Sci. 2002 Oct;91 (10) :2193-202.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
CYP2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC472848-100 1x 100 µL
Fibronectin (Fn-3), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470679-500 1x 500 µL
CD171 / L1CAM (L1 Cell Adhesion Molecule) (UJ127), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880009-100 1x 100 µL
MART-1 / Melan-A (M2-7C10), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC041037-100 1x 100 µL
CD44 Standard (DF1485), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680257-100 1x 100 µL
Cytokeratin, HMW (AE-3), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details